Intellectual Property - February 4, 2020
AroCell has submitted a new patent application
A patent application has been submitted regarding the use of an immunoassay of Thymidine Kinase 1 (TK1) to enable more accurate prognoses in prostate cancer patients. In the study, on which this patent application is based, TK1 protein levels were assayed with AroCell TK 210 ELISA in serum samples collected from subjects with newly diagnosed […]
Intellectual Property - December 17, 2019
Follicum receives patent grant in the US
Follicum announced on September 17, 2019 that the company had received a Notice of Allowance from the US Patent and Trademark Office regarding the patent application “Novel Compositions and Uses Thereof”. The patent has now formally been granted by the USPTO. The patent is valid until 2032. In this patent family, Follicum already has two […]
Intellectual Property - November 4, 2019
Lobsor Pharmaceuticals granted Japanese patent
Lobsor Pharmaceuticals has announced the Japanese Patent Office has issued a Decision to Grant a patent covering Lecigon a new therapeutic system for symptomatic treatment of Advanced Parkinson’s Disease (APD). Lecigon is a proprietary pharmaceutical gel formulation containing a combination of levodopa/carbidopa and entacapone for continuous infusion into the small intestine through a newly developed […]
Intellectual Property - October 16, 2019
An opposition has been filed against one of Cantargia’s patents
An opposition has been filed against one of the European patents in Cantargia’s patent family covering antibody therapy in solid tumors. The patent confers protection for e.g. IL1RAP targeted antibodies in tumor forms not already covered in the European mother patent, which was granted in 2016. The current opponent, Mab Discovery GmbH, also filed an […]
Intellectual Property - October 11, 2019
ChemoTech obtains two patent approvals
The company has received the final notice from the Swedish patent Authorities (PRV) for two of its patent applications. ChemoTech is a Swedish medtech company that has developed a technology platform to offer cancer patients who cannot be treated with conventional methods access to a new treatment alternative, Dynamic-ElectroEnhanced Chemotherapy (D-EECT). These new patents will […]
Intellectual Property - August 30, 2019
Gradientech announces Notice of Allowance
The company has received a Notice of Allowance from the United States Patent and Trademark Office for the patent application no. 14/903,032, “Use of a Fluidic Device”. The patent application covers the proprietary minimum inhibitory concentration (MIC) determination of a bacterial sample within a microfluidic controlled environment that is part of the technology platform of […]
